Nachrichten zur Bristol-Myers Squibb Co Aktie

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.27, marking a +1.18% move from the previous day.…

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.…

Bristol Myers vs. Pfizer: Which High?Yield Dividend Stock Wins Now?

Whichever one you choose, youll need patience before you can see solid returns.…

BioNTech mit neuen Daten – doch reicht das?

BioNTech und der Partner Bristol Myers Squibb haben am Wochenende auf dem ASCO-Meeting in Chicago neue Zwischenergebnisse der Phase-2/3-Studie ROSETTA-Lung-02…

GNW-News: Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

^* Erster bispezifischer PD-(L)1xVEGF-Immunmodulator-Kandidat, zu dem globale Daten mit ermutigender Wirksamkeit in Kombination mit Chemotherapie in der…

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech and BMS PD-L1xVEGF-A bispecific pumitamig shows encouraging efficacy in patients with non-small cell lung cancer in ROSETTA Lung-02 trial…

UBS reiterates Bristol-Myers Squibb stock rating on pipeline potential

UBS reiterates Bristol-Myers Squibb stock rating on pipeline potential…

Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.

The numbers dont tell the full story with this big pharma stock.…

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave…

Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

…

Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.

This may be an excellent deal for those focused on the long game.…

IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading

Global IgG4-related disease market sees growth due to increased research funding and development of targeted therapies. This rare autoimmune condition…

GNW-News: BioNTech veröffentlicht Ergebnisse für das erste Quartal 2026 sowie Informationen zur Geschäftsentwicklung

^* Fünf zusätzliche zulassungsrelevante Studien für Pumitamig in Zusammenarbeit mit Bristol Myers Squibb seit Jahresbeginn initiiert …

Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing

…

Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook

Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook…

Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales

Bristol Myers Squibb reported a first-quarter profit that beat Wall Street expectations on Thursday, helped by better-than-expected growth of blood…

Is Bristol Myers Squibb the Best Bargain in Big Pharma?

This pharma stock is cheap for a reason.…

Bristol Myers Squibb: Low Volatility Meets High Dividend Yield

Volatility and dividend yield are important metrics for investors thinking about a long-term buy.…

Bristol Myers Squibb: Low Volatility Meets High Dividend Yield

Volatility and dividend yield are important metrics for investors thinking about a long-term buy.…

Atrium Therapeutics earns $15M from Bristol Myers Squibb

Atrium Therapeutics earns $15M from Bristol Myers Squibb…

Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff

…

Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.96, denoting a +1.85% move from…

Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.96, denoting a +1.85% move from…

Which Dividend Pharma Stock Should a Value Investor Choose Today?

Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong.…

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note

The latest trading day saw Bristol Myers Squibb (BMY) settling at $60.65, representing a +1.54% change from its previous close.…

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from…

Will the Recent Label Expansion of BMYs Opdivo Boost Its IO Franchise?

Bristol Myers Squibbs Opdivo expansions highlight pharma companies push to grow oncology franchises amid rising competition and pipeline innovation.…

Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?

The healthcare company has been a top dividend growth stock for years.…

Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty

Bristol-Myers Squibb stock remains a "Buy" given its high dividend, strong free cash flow yield, and valuation. Learn more about…

Evotec: Positive News verpuffen – Aktie fällt erneut

Auch eigentlich gute Meldungen prallen an der Aktie von Evotec derzeit einfach ab. Beim Hamburger Wirkstoffforscher klingelt die Kasse: Das…

Heres Why Bristol Myers Squibb (BMY) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Bristol Myers Squibb (BMY) settling at $59.71, representing a +1.07% change from its previous close.…

Why Bristol Myers Squibb Stock Crushed it in February

It delivered for shareholders in its fourth quarter of 2025 with a double beat on analyst projections.…

Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, Bristol Myers Squibb (BMY) closed at $60.74, marking a -2.55% move from the previous day.…

Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven?Figure Retirement

Bristol Myers Squibb has an attractive 4% yield and a strong dividend history.…

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.37, marking a +2.08% move from the previous day.…

ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value

By M. MarinNASDAQ:ORMPREAD THE FULL ORMP RESEARCH REPORTTransaction enables exposure to both oral drug delivery program & medical device businessesOramed…

Down 25%, Should You Buy the Dip on Bristol Myers Squibb?

The pharma industrys dreaded patent cliff is a key driver of the stocks decline.…

Waters (WAT) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEThursday, Feb. 12, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Udit BatraChief Financial Officer…

Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026

…

Bristol Myers Squibb CEO: Richest product pipeline weve had in the last decade

Chris Boerner, Bristol Myers Squibb CEO, joins CNBCs "Power Lunch" to discuss the companys quarterly earnings results, the drug pipeline…

PLX: CHMP Delivers Positive Opinion

By John Vandermosten, CFANYSE:PLXREAD THE FULL PLX RESEARCH REPORTCHMP Positive Opinion for Elfabrio Four-Week DosingIn October 2025, Protalix BioTherapeutics, Inc.…

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

Bristol Myers (BMY) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

Bristol Myers Squibb (BMY) closed the most recent trading day at $54.62, moving 1.69% from the previous trading session.…

Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)

…

Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion

…

BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?

Bristol Myers Squibb and GSK stack up differently on growth, debt, pipelines and returns, making the stock-picking decision far from…

Microsoft: Mit KI im Kampf gegen Krebs – Deal mit Pharma-Riesen

Der Einsatz von Künstlicher Intelligenz (KI) könnte die Diagnose von Krebs revolutionieren. Daran glaubt offenbar auch der Pharma-Konzern Bristol Myers…

Microsoft: Mit KI im Kampf gegen Krebs – Deal mit Pharma-Riesen

Der Einsatz von Künstlicher Intelligenz (KI) könnte die Diagnose von Krebs revolutionieren. Daran glaubt offenbar auch der Pharma-Konzern Bristol Myers…